Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude

Experimental and Therapeutic Medicine

Volumn 6, Issue 3, 2013, Pages 747-752

  Feng, Enzhi ^a   Wan, Ronghua ^b   Yang, Shengyue ^a   Yan, Ziqiang ^a   Wang, Shaolin ^a   He, Wei ^a   Zhang, Ying ^a   Yin, He ^a   Chen, Zongru ^a   Liu, Ruinian ^a  

^a Fourth Hospital of Chinese PLA   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

2 adrenoceptor agonist; Chronic cor pulmonale; Chronic obstructive pulmonary disease; Corticosteroid; Interleukin 10; Interleukin 8

Indexed keywords

BUDESONIDE; FLUTICASONE; INTERLEUKIN 10; INTERLEUKIN 8; SALMETEROL;

ADULT; AGED; ALTITUDE; ARTICLE; BLOOD CARBON DIOXIDE TENSION; BLOOD OXYGEN TENSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COR PULMONALE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS;

EID: 84880502863     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1192     Document Type: Article

References (30)

1. Agustí A and Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184: 507-513, 2011.
2. Dalal AA, Liu F and Riedel AA: Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis 6: 533-542, 2011.
3. Lopez AD, Shibuya K, Rao C, et al: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27: 397-412, 2006.
4. Rabe K F, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555, 2007.
5. Parr DG, White AJ, Bayley DL, Guest PJ and Stockley RA: Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res 7: 136, 2006.
6. GOLD Executive Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2011) [EB/OL]. http://www.goldcopd.com. Accessed February 22, 2012.
7. Asadullah K, Sterry W and Volk HD: Interleukin-10 therapy -review of a new approach. Pharmacol Rev 55: 241-269, 2003.
8. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB and Temel I: Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 100: 846-854, 2006.
9. Ko FW, Leung TF, Wong GW, et al: Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 4: 79-86, 2009.
10. O'Donnell R, Breen D, Wilson S and Djukanovic R: Inflammatory cells in the airways in COPD. Thorax 61: 448-454, 2006.
11. Kochetkova EA, Volkova M V, Surovenko TN and Gel'tser BI: Cytokine status in patients with chronic obstructive pulmonary diseases and its relationship with bone tissue functional state. Ter Arkh 76: 23-27, 2004 (In Russian).
12. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators: Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789, 2007.
13. COPD Working Group of Chinese Medical Association respiratory disorder branch. Guidelines for the Diagnosis and Treatment of COPD (2007 Revised Edition). Chin J Tuberc Respir Dis 30: 8-17, 2007 (In Chinese).
14. Chen HZ (ed): Practical Internal Medicine. 11th edition. People's Health Publishing House, Beijing, pp1449-1452, 2001.
15. Oudin S and Pugin J: Role of MAP kinase activation in inter-leukin-8 production by human BEAS-2B bronchial epithelial cells submitted to cyclic stretch. Am J Respir Cell Mol Biol 27: 107-114, 2002.
16. Powrie DJ, Wilkinson TM, Donaldson GC, et al: Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30: 472-478, 2007.
17. Chung KF: Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 4: 619-625, 2005.
18. Gong MN, Thompson BT, Williams PL, et al: Interleukin-10 polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J 27: 674-681, 2006.
19. Wilson SJ, Wallin A, Della-Cioppa G, Sandström T and Holgate ST: Effect of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 164: 1047-1052, 2001.
20. Kersul AL, Iglesias A, Ríos Á, et al: Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 47: 176-183, 2011.
21. Takanashi S, Hasegawa Y, Kanehira Y, et al: Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 14: 309-314, 1999.
22. Burgess JL, Nanson CJ, Hysong TA, Gerkin R, Witten ML and Lantz RC: Rapid decline in sputum IL-10 concentration following occupational smoke exposure. Inhal Toxicol 14: 133-140, 2002.
23. Liu SX, Zhang GJ, Wang HQ, Chen SS and Chu HY: Effect of inhaled glucocorticoids/long-acting β2-agonist on chronic obstructive pulmonary disease. International Journal of Respiration 29: 129-131, 2009 (In Chinese).
24. Barnes NC, Qiu YS, Pavord ID, et al; SCO30005 Study Group: Anti-inflammatory effects of salmeterol/formoterol propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173: 736-743, 2006.
25. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R and Hamid Q: Effect of salmeterol/futicasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 62: 938-943, 2007
26. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332-338, 2008.
27. Fenton C and Keating GM: Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. Drugs 64: 1975-1996, 2004.
28. Marwick VM and Chung KF: Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 5: 297-309, 2010.
29. Patel IS, Roberts NJ, Lloyd-Owen SJ, Sapsford RJ and Wedzicha JA: Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 22: 94-99, 2003.
30. Armstrong J, Harbron C, Lea S, et al: Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 338: 732-740, 2011.